Biocon expects recovery in generics business in FY23:

biocon

The pharma company said that it expects recovery in generics business in FY23.

Margin improvement in biosimilars aided by developed markets. Expect improvement in Semglee market share in CY22. Near-term focus is COVID-19 vaccines with serum.

See the biosimilar business gaining momentum. No visibility on when the inspection for Bevacizumab will be done. Have asked US FDA to even consider a remote inspection for Bevacizumab.

News Source:- Moneycontrol

For Enquiry Fill The Form

    *Note:- Please provide a valid Email Id to receive OTP from bigprofitbuzz.com.

    Facebook Iconfacebook like buttonYouTube IconTwitter Icontwitter follow button